Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
about
Toll-like receptor 9 in breast cancer.DNA from dead cancer cells induces TLR9-mediated invasion and inflammation in living cancer cellsClinical evaluation of CpG oligonucleotides as adjuvants for vaccines targeting infectious diseases and cancer.Tumor infiltrating CD8(+) T lymphocyte count is independent of tumor TLR9 status in treatment naïve triple negative breast cancer and renal cell carcinomaRegulation of migration and invasion by Toll-like receptor-9 signaling network in prostate cancer.Breast cancer as a systemic disease: a view of metastasisAssociation between TLR-9 polymorphisms and colon cancer susceptibility in Saudi Arabian female patients.Biopathological Significance of TLR9 Expression in Cancer Cells and Tumor Microenvironment Across Invasive Breast Carcinomas Subtypes.Toll-like receptor 9 expression is associated with breast cancer sensitivity to the growth inhibitory effects of bisphosphonates in vitro and in vivo.Mutations in components of antiviral or microbial defense as a basis for breast cancer.Cell membrane and intracellular expression of toll-like receptor 9 (TLR9) in colorectal cancer and breast cancer cell-lines.Hybrid Cells Derived from Human Breast Cancer Cells and Human Breast Epithelial Cells Exhibit Differential TLR4 and TLR9 Signaling.Telomeric G-quadruplex-forming DNA fragments induce TLR9-mediated and LL-37-regulated invasion in breast cancer cells in vitro.Toll-like receptor 9 mediates invasion and predicts prognosis in squamous cell carcinoma of the mobile tongue.Toll-like receptor 9 expression in mucoepidermoid salivary gland carcinoma may associate with good prognosis.High toll-like receptor (TLR) 9 expression is associated with better prognosis in surgically treated pancreatic cancer patients.Hypoxia regulates Toll-like receptor-9 expression and invasive function in human brain cancer cells in vitro.Lower frequency of TLR9 variant associated with protection from breast cancer among African Americans.Chloroquine has tumor-inhibitory and tumor-promoting effects in triple-negative breast cancer.Expression of Toll-like receptor-9 is associated with poor progression-free survival in prostate cancerTrial Watch: Toll-like receptor agonists for cancer therapy.Repurposing Drugs in Oncology (ReDO)-chloroquine and hydroxychloroquine as anti-cancer agents.Toll-like receptor 9 activation by CpG oligodeoxynucleotide 7909 enhances the radiosensitivity of A549 lung cancer cells via the p53 signaling pathway.TLR9 signaling activation at different stages in colorectal cancer and NF-kappaB expression
P2860
Q33928402-80C47118-1ED1-405A-9A7A-1A167D7EB399Q34549200-7E10F9D0-494F-4BF6-9D20-3B20BC946260Q34613585-D4B80235-2094-4FCC-B68E-22D8F8C45468Q35798941-A8C8594B-CF9C-48C7-8515-BDDB33FAAC40Q36356021-1ACE4CD2-4C99-4A8E-9748-3CA7E0A0D47DQ37011741-AE439768-C41E-4BBE-A5BA-FE2EA42A94BBQ37527855-2FCBEF03-F5B8-4B3B-91F7-8442C0BE4545Q37605221-73D865A3-CAAA-4AB3-BC4B-538B9FB4FDB7Q37699431-12BB658F-5291-47F3-8095-1E2788873F43Q38140679-E9E01AAA-CAEA-403E-9AA2-867462CF7A77Q38720388-7A72DF9F-A04D-4C4C-A5C4-6E86A4883127Q38770438-9AAF60FF-A344-4312-AA5D-E1ED976A068DQ38802341-F046E0EC-C651-469E-A2B9-A95904F480A9Q38945757-B6ED41BA-E1FD-4245-A52A-29FF6964B42FQ39028490-64A96DC3-0635-4D51-BBA1-9F65612E3AFEQ40338679-8EE9A915-D8FA-4515-9B54-349CF56842A6Q40893702-1F6B48D9-8B7A-434F-88BA-BC5526BDE227Q41497232-BBB88CF6-68FA-4F6D-B0BD-69DAEA38B69DQ41923347-42F1A6DD-CA10-4ECA-8A27-DDC5EAAF7AB3Q42149484-B1C8F56B-6F06-4259-BF88-3148F3C50D82Q42969291-49A75C38-FC90-4A13-9F0A-C0292EBF67D2Q47162451-0729AEA5-D452-44D6-A7C7-27D0E0AA0BF9Q54121240-FA534CE9-F2FA-46C5-9FAC-FC0484CE6897Q57073978-79297883-5C5E-4779-96B3-725D44B7AE0E
P2860
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年学术文章
@wuu
2012年学术文章
@zh-cn
2012年学术文章
@zh-hans
2012年学术文章
@zh-my
2012年学术文章
@zh-sg
2012年學術文章
@yue
2012年學術文章
@zh
2012年學術文章
@zh-hant
name
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@en
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@nl
type
label
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@en
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@nl
prefLabel
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@en
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@nl
P2093
P2860
P1476
Low TLR9 expression defines an aggressive subtype of triple-negative breast cancer.
@en
P2093
Christine Pressey
David Graves
Dongquan Chen
Joanna Ilvesaro
Johanna Tuomela
Joonas H Kauppila
Jouko Sandholm
Katri S Selander
Katri S Vuopala
Kevin W Harris
P2860
P2888
P304
P356
10.1007/S10549-012-2181-7
P407
P577
2012-07-31T00:00:00Z